Chronic Kidney Disease Trial, Recruiting (NCT06032208)

Chronic Kidney Disease Trial, Recruiting NCT06032208 Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's Condition: Chronic Kidney Disease

Printed from Voxsanity (voxsanity.com.au) — NCT06032208 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Chronic Kidney Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who receive hemodialysis (kidney dialysis) three times per week on a standard schedule
People who have been on regular hemodialysis for at least 3 months
People aged 18 years or older
People who are willing and able to give their formal agreement to take part in the study

Who may not be able to join:

People who currently have an active infection (enrollment may be possible once the infection has cleared)
People who receive hemodialysis every day rather than three times per week
People who have received certain types of advanced dialysis treatments — called Hemodiafiltration, Hemofiltration, or Isolated Ultrafiltration — more than once in the past three months (confirm with trial site)
People who have a visual impairment
People who have a history of cognitive or neurological conditions affecting thinking, memory, or brain function
People who have previously had a stroke

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 15 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Christopher McIntyre, MBBS DM, London Heath Sciences Centre

Phone: 5196858500

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06032208

Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Phase: Not Applicable

Status: Recruiting

Condition: Chronic Kidney Disease

Trial contact: 5196858500

More information: https://clinicaltrials.gov/study/NCT06032208

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who receive hemodialysis (kidney dialysis) three times per week on a standard schedule
People who have been on regular hemodialysis for at least 3 months
People aged 18 years or older
People who are willing and able to give their formal agreement to take part in the study

Who may not be able to join:

People who currently have an active infection (enrollment may be possible once the infection has cleared)
People who receive hemodialysis every day rather than three times per week
People who have received certain types of advanced dialysis treatments — called Hemodiafiltration, Hemofiltration, or Isolated Ultrafiltration — more than once in the past three months (confirm with trial site)
People who have a visual impairment
People who have a history of cognitive or neurological conditions affecting thinking, memory, or brain function
People who have previously had a stroke

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 15 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Registry

ClinicalTrials.gov

Start date

1 March 2024

Est. completion

31 December 2026

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Determine if the clearance of larger middle molecular weight toxins using medium-cut-off dialyzer (HDx -Theranova) effects patient reported symptoms as determined by LEVIL.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov